Low-dose 123I-metaiodobenzylguanidine diagnostic scan is inferior to 131I-metaiodobenzylguanidine posttreatment scan in detection of malignant pheochromocytoma and paraganglioma

Nuclear Medicine Communications

Volumn 32, Issue 10, 2011, Pages 941-946

  Kayano, Daiki ^a   Taki, Junichi ^a   Fukuoka, Makoto ^a   Wakabayashi, Hiroshi ^a   Inaki, Anri ^a   Nakamura, Ayane ^a   Kinuya, Seigo ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

123I; 131I; metaiodobenzylguanidine; paraganglioma; pheochromocytoma

Indexed keywords

METAIODOBENZYLGUANADINE I 123; METAIODOBENZYLGUANADINE I 131; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DRUG UPTAKE; FEMALE; HUMAN; IMAGE ANALYSIS; LOW DRUG DOSE; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SCINTIGRAPHY; WHOLE BODY IMAGING;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; ADULT; AGED; BIOLOGICAL TRANSPORT; FEMALE; HUMANS; MALE; MIDDLE AGED; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RADIATION DOSAGE; REPRODUCIBILITY OF RESULTS; TIME FACTORS; WHOLE BODY IMAGING;

EID: 80052468412     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834a4445     Document Type: Article

References (28)

1. Jaques S Jr., Tobes MC, Sisson JC. Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Res 1987; 47:3920-3928. (Pubitemid 17108446)
2. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 2004; 89:479-491. (Pubitemid 38269845)
3. Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 1980; 21:349-353. (Pubitemid 10100562)
4. Nakajo M, Shapiro B, Copp J, Kalff V, Gross MD, Sisson JC, et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med 1983; 24:672-682. (Pubitemid 13016087)
5. Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 1981; 305:12-17. (Pubitemid 11071190)
6. Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 1985; 26:576-585. (Pubitemid 16033416)
7. Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999; 43:217-223. (Pubitemid 29500578)
8. Rufini V, Castaldi P, Treglia G, Perotti G, Gross MD, Al-Nahhas A, et al. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother 2008; 62:139-146. (Pubitemid 351381932)
9. Jacobson AF, Deng H, Lombard J, Lessig HJ, Black RR. 123I-meta- iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab 2010; 95:2596-2606.
10. Furuta N, Kiyota H, Yoshigoe F, Hasegawa N, Ohishi Y. Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzyl-guanidine scintigraphy. Int J Urol 1999; 6:119-124. (Pubitemid 30406825)
11. Koopmans KP, Neels ON, Kema IP, Elsinga PH, Links TP, de Vries EG, et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol 2009; 71: 199-213.
12. Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, Sippel RS, et al. Pheochromocytoma: current approaches and future directions. Oncologist 2008; 13:779-793.
13. Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010; 37:2436-2446.
14. Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol 2009; 27:5343-5349.
15. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 2009; 50:1237-1243.
16. Papathanasiou ND, Gaze MN, Sullivan K, Aldridge M, Waddington W, Almuhaideb A, et al. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis. J Nucl Med 2011; 52:519-525.
17. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2009; 94:4757-4767.
18. Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodo-benzylguanidine. Eur J Nucl Med Mol Imaging 2011; 38:865-873.
19. Campbell L, Mouratidis B, Sullivan P. Improved detection of disseminated pheochromocytoma using post therapy I-131 MIBG scanning. Clin Nucl Med 1996; 21:960-963. (Pubitemid 26412221)
20. Fukuoka M, Taki J, Mochizuki T, Kinuya S. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/ paraganglioma and neuroblastoma. Clin Nucl Med 2011; 36:1-7.
21. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006; 36:228-247. (Pubitemid 43817847)
22. 131I therapy. Nucl Med Commun 2006; 27:165-169. (Pubitemid 44391826)
23. Iwano S, Kato K, Nihashi T, Ito S, Tachi Y, Naganawa S. Comparisons of I-123 diagnostic and I-131 post-treatment scans for detecting residual thyroid tissue and metastases of differentiated thyroid cancer. Ann Nucl Med 2009; 23:777-782.
24. Donahue KP, Shah NP, Lee SL, Oates ME. Initial staging of differentiated thyroid carcinoma: continued utility of posttherapy 131I whole-body scintigraphy. Radiology 2008; 246:887-894.
25. Gedik GK, Hoefnagel CA, Bais E, Olmos RA. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008; 35:725-733.
26. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight GS Jr., et al. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery. 2003; 134:956-962; discussion 962-963.
27. Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, et al. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci 2006; 1073:465-490.
28. Olivier P, Colarinha P, Fettich J, Fischer S, Frokier J, Giammarile F, et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging 2003; 30:B45-B50.